Gt biopharma names charles j. casamento to the board of directors

Brisbane, california, may 04, 2023 (globe newswire) -- gt biopharma, inc. (the “company”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, has named charles j. casamento to fill a vacant seat on the board and to serve as a member of the audit committee of the board, the compensation committee of the board and the nominating and corporate governance committee of the board as of may 1, 2023. concurrently, alan urban resigned as a member of the board of directors (the “board”) in order to pursue new career endeavors.
GTBP Ratings Summary
GTBP Quant Ranking